51 results about "Vancomycin" patented technology

The invention belongs to the technical field of biology, and particularly relates to bifidobacterium longum subsp.infantis FMBL B250020GXY for metabolizing breast milk oligosaccharide and application of the bifidobacterium longum subsp.infantis FMBL B250020GXY, the bifidobacterium longum subsp.infantis FMBL B250020GXY is preserved in China Center for Type Culture Collection on September 1, 2025, and the preservation number is CCTCC M 20251931; three kinds of breast milk oligosaccharides, namely 2 '-fucosyllactose (2'-FL), lactose-N-neotetraose (LNnT) and lactose-N-tetraose (LNT), can be metabolized; plant source carbohydrates such as fructo-oligosaccharide and synanthrin can be metabolized; the compound has a relatively strong capability of removing DPPH and ABTS free radicals; a good inhibition effect is achieved on common pathogenic bacteria; good tolerance to acid and cholate is achieved; the strain is sensitive to gentamicin, streptomycin, tetracycline, chloramphenicol and vancomycin; the compound can be used for preparing antioxidant products, medicines for inhibiting pathogenic bacteria, infant foods and fermented foods, and has a wide application prospect.

The application discloses a material for preventing tissue adhesion and hemostasis and a preparation method thereof, and relates to the technical field of medical biomaterials.The carboxymethyl cellulose, chitosan and vancomycin / ceftazidime are synergistically matched, so that the three functions of hemostasis, adhesion prevention and antibiosis are integrated;meanwhile, the water absorption and gelation of the carboxymethyl cellulose and the blood coagulation activation of the chitosan can jointly strengthen the hemostasis effect; the tissue barrier function of the chitosan and the gel isolation of the carboxymethyl cellulose can jointly improve the adhesion prevention performance; the broad-spectrum antibiosis of the vancomycin and the ceftazidime can respond to the infection risk in different surgical scenes; the material preparation process is simple, the dosage form can be adjusted according to different surgical scenes, the material has good biocompatibility and can be completely degraded, the problem that the existing medical materials have single function and are difficult to meet the needs of complex surgical wounds is solved, and the material has significant clinical application value.

The invention relates to the technical field of materials for preventing and treating local infection, in particular to drug-loaded composite nanoparticles as well as a preparation method and application thereof. The drug-loaded composite nanoparticles provided by the invention comprise hollow polydopamine grafted with vancomycin and lipoic acid-quaternary ammonium salt ionic liquid loaded into a cavity of the hollow polydopamine. In the invention, the HPDA nanoparticles have a hollow structure, and the structure provides sufficient space for loading of drug molecules. The lipoic acid-quaternary ammonium salt ionic liquid can generate heat energy under the microwave heat effect, and bacteria are effectively killed. Besides, under microwave stimulation, the lipoic acid-quaternary ammonium salt ionic liquid not only can enhance the sterilization effect, but also can reduce inflammatory response caused by bacterial infection through the synergistic effect of microwave heat effect and chemical sterilization.

The invention discloses antibiotic-loaded in-situ modified platelet-rich fibrin gel as well as a preparation method and application thereof. The antibiotic-loaded in-situ modified platelet-rich fibrin gel is prepared from the following components in percentage by mass: 88 to 92 percent of PRF (platelet-rich fibrin) matrix, 5 to 8 percent of antibiotic and 3 to 4 percent of modifier, the PRF matrix comprises platelets, leukocytes and fibrin, the antibiotic is vancomycin or gentamicin, and the modifier is a zinc ion-containing compound or quaternized chitosan. The gel can be applied to preparation of chronic infection wound dressing, the antibiotic loading rate of the gel is increased, the gel has the slow release characteristic, the accumulative release within 7 days is 82.3 + / -5.6%, the burst release within 24 hours is less than 15%, the wound healing speed is increased by 40%, and the biological membrane clearance rate is 100%.

The application discloses a food-borne pathogenic bacteria detection method based on composite nanomaterials and belongs to the technical field of food safety detection. The method is characterized by the following steps: synthesizing cerium-based nanomaterial DPA-Ce-GMP with enzyme-like activity based on Ce(CH3COO)3, guanosine-5'-monophosphate disodium (GMP) and 2,6-pyridine dicarboxylic acid (DPA); taking Prussian blue as a carrier; using vancomycin to identify gram-positive bacteria; and constructing a composite nanomaterial PB@DPA-Ce-GMP@Van with targeting and oxidase characteristics, namely PCV. The PCV can be precisely adsorbed on the surface of gram-positive bacteria to form a PCV / gram-positive bacteria composite. The residual PCV in the supernatant after centrifugation can quench the fluorescence of scopolamine (SC) and increase the fluorescence intensity of fluorescent red dye (AR) at the same time. The fluorescence intensity ratio (SC / AR) is used as a detection signal output. The application realizes a composite nanometer platform for rapid detection of bacteria, has high sensitivity and strong anti-interference ability, and has a detection range of 10 1 ~ 10 7 CFU / mL and a detection limit of 5 CFU / mL.

The invention relates to the technical field of biology, in particular to a broad-spectrum bacteriophage lyase mutant, an extraction and purification reagent and a kit. The invention provides a broad-spectrum bacteriophage lyase mutant, an extraction and purification reagent and a kit. A broad-spectrum bacteriophage lyase mutant nucleic acid release liquid containing protein with an amino acid sequence as shown in SEQ ID NO: 1 is adopted; the compound can efficiently act on two important clinical drug-resistant bacteria, namely methicillin-resistant staphylococcus aureus MRSA and vancomycin-resistant enterococcus VRE, at the same time. Through unique molecular design and preparation process optimization, the lyase shows excellent synchronous wall breaking capacity, cell wall destruction can be completed in an extremely short time, and the nucleic acid release efficiency is remarkably superior to that of a traditional method.

The application discloses a kind of smelly danchang dots and preparation method and application, belong to medical technical field.The preparation method of smelly danchang dot includes: smelly danchang fine powder is dispersed in distilled water, and is stirred pyrolysis on heating table;Pyrolysis product is diluted with distilled water, and supernatant is obtained by centrifugation, filter membrane filtration, dialysis, freeze-drying, to obtain carbon dot.The average particle size of obtained carbon dot is 4.51±1.04nm.The smelly danchang dot prepared in the application shows strong inhibitory activity to a variety of gram-positive bacteria (such as listeria, methicillin-resistant staphylococcus aureus MRSA) and fungi (such as Candida albicans), especially to clinically tricky drug-resistant strains, such as vancomycin-resistant enterococci (VRE) and MRSA effective, can be applied to the preparation of antibacterial drugs, antibacterial dressing, disinfectant or preservative, with the advantages of wide raw material source, simple preparation method, low cost, environment-friendly and the like.

This invention discloses the application of the bacterial fission protein FtsZ inhibitor DB1 in the preparation of drugs against drug-resistant bacteria, belonging to the field of drug development technology. The inhibitor provided by this invention is compound DB1, named 3-(2,8-dibromo-10,11-dihydro-5H-dibenzo[b,f]azapheno-5-yl)-N,N-dimethylpropylamine hydrochloride, with the molecular formula C2. 19 H 24 Br2ClN2. This compound, DB1, exhibits significant inhibitory effects against various drug-resistant bacteria, particularly vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus (MRSA), and can significantly improve the susceptibility of methicillin to MRSA. The discovery of compound DB1 provides new ideas and technical support for the preparation of drugs against drug-resistant bacteria.

The invention relates to a double-probe detection kit for detecting staphylococcus aureus in meat products and a preparation method of the double-probe detection kit, and belongs to the technical field of food safety. The double-probe detection kit is composed of a magnetic capture probe reagent and a double-signal nano-enzyme probe reagent which are independently packaged and have the same volume; the magnetic capture probe reagent is a vancomycin modified reticular magnetic bead and is used for specifically binding staphylococcus aureus in a meat product detection sample and carrying out separation and enrichment treatment; the double-signal nano-enzyme probe reagent is a blue fluorescent carbon dot modified by a nucleic acid aptamer and is used for specifically combining the staphylococcus aureus subjected to separation and enrichment treatment and generating a staphylococcus aureus concentration dependent colorimetric signal and a fluorescent signal. According to the invention, mutual verification is carried out between dual-mode signals, so that the accuracy of a detection result is improved; according to the method, the detection time is within 1.5 h, the detection time is short, the detection sensitivity is high, and the method has good specificity for common type strains.

The invention discloses an aromatic polyketone compound as well as a preparation method and application thereof. The compound GaB (3) has an effect of treating infection of multiple drug-resistant bacteria. The compound is obtained by being separated from a secondary metabolite of the symbiotic Streptomyces sp.QHH-9511 of licheniformis, and the compound 2, the compound 3, the compound 4 and the compound 5 are new compounds. According to the present invention, the research results show that the GaB can effectively sterilize a variety of drug-resistant bacteria (methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, carbapenem-resistant acinetobacter baumannii, multi-drug-resistant pseudomonas aeruginosa, multi-drug-resistant salmonella, and the like); in addition, the compound has the characteristics of broad-spectrum sterilization, biofilm formation inhibition and low-frequency drug resistance, and can be combined with other antibiotics to cope with super bacteria. Mechanism research shows that GaB is combined with glucosamine-6-phosphate synthetase (GlmS) to prevent synthesis of cell walls so as to play an antibacterial role, and a plurality of constructed living body models show that the compound can effectively reduce the content of bacteria in a body and promote wound repair and has in-vivo medication safety. The research result shows that the GaB can be used as a safe and effective novel pilot natural active small molecule for resisting infection of multiple drug-resistant bacteria.

Compositions and methods are provided for the synthesis and use of biguanide-conjugated antibiotics, which provide a generalizable strategy for rapidly synthesizing potent antibiotics derived from clinically relevant agents.

The invention discloses a betulinic acid derivative as well as a synthesis method and application thereof. According to the betulinic acid derivative, the carboxyl position of betulinic acid C-28 is subjected to structural modification, and four halogenated aniline derivatives are obtained. Wherein the derivatives b, d and e show strong activity on staphylococcus aureus, the derivatives d and e also show strong activity on vancomycin-resistant staphylococcus aureus (VRSA), and the derivative o strongly inhibits streptococcus pneumoniae. Compared with a parent skeleton, the four derivatives show significantly enhanced antibacterial efficacy. Experimental data prove that the derivatives d and e and further derivatives thereof may provide a promising strategy for resisting drug-resistant gram-positive pathogens, and the derivative d can be further developed into a novel therapeutic agent for biofilm-mediated drug-resistant infection.

The application belongs to the technical field of high-performance polypropylene, and discloses an antibacterial polypropylene composite material, a preparation method thereof and a medicine bottle. The antibacterial polypropylene composite material is prepared from polypropylene, composite antibacterial particles, a lubricant and the like; wherein the polypropylene is 78-87.3%, the composite antibacterial particles are 10-18%, the lubricant is 1-2%, the antioxidant is 0.5%-2%, the toughening agent is 1%-3%, and the nucleating agent is 0.2%-0.3%. The antibacterial polypropylene composite material has high antibacterial performance and mechanical performance. In addition to having antibacterial effects on common bacteria such as Escherichia coli and Staphylococcus aureus, the antibacterial polypropylene composite material has significant antibacterial activity on drug-resistant bacteria such as vancomycin-resistant Enterococcus (VRE) and methicillin-resistant Staphylococcus aureus (MRSA), which shows the outstanding antibacterial characteristics of the antibacterial polypropylene composite material.

The application discloses an antibody-antibiotic conjugate and application thereof, and a structural formula of the antibody-antibiotic conjugate is shown as formula (I) and is composed of a payload antibiotic, a monoclonal antibody targeting Kdo monosaccharide and an enzyme-sensitive linker; the antibody-antibiotic conjugate has strong affinity to Kdo antigen and can be combined with Staphylococcus aureus of different serotypes. Enzymatic treatment of the antibody-antibiotic conjugate can release free antibiotics to improve the bactericidal efficiency on Staphylococcus aureus; the antibody-antibiotic conjugate can effectively kill intracellular bacteria which are difficult to be affected by traditional small-molecule antibiotics through the mediation of the antibody; in the application of a Staphylococcus aureus-induced mouse pneumonia and nephritis model, the antibody-antibiotic conjugate can effectively remove bacteria in the lung and kidney, and the therapeutic effect is better than that of vancomycin. Therefore, the antibody-antibiotic conjugate has potential application in the development of Staphylococcus aureus infection drugs.

The invention belongs to the technical field of organic synthesis, and provides a honokiol phosphine salt derivative as well as a preparation method and application thereof, and a novel magnolol derivative is designed and synthesized by integrating a cationic head group and a hydrophobic chain. The compound shows potent activity (MIC = 1-4 [mu] g / mL) on a series of gram-positive bacteria, meanwhile, the hemolytic activity is extremely low (HC50 = 106.9 [mu] g / mL), and the cytotoxicity is also low (CC50 = 19.25 [mu] g / mL). In addition, the derivative also has the capabilities of rapid sterilization, low drug resistance, good plasma stability and capability of inhibiting biofilm formation and destroying mature biofilms. And compared with vancomycin, the vancomycin-containing antibacterial peptide has the advantage that the bacterial load can be obviously reduced.

The application discloses a strain of Flammulina velutipes, a fermentation liquor of the strain and application thereof, and belongs to the technical field of microorganisms.The Flammulina velutipes strain R12 is preserved in the Guangdong Provincial Microbial Culture Collection Center on August 18, 2025, the address of the preservation center is No. 59 Building, 5th Floor, Guangzhou Xianlie Middle Road 100, and the preservation number is GDMCC NO. 66855.The fermentation liquor of the Flammulina velutipes strain R12 disclosed by the application has a specific bacteriostatic effect on vancomycin moderately drug-resistant Staphylococcus aureus XN108, and provides an important candidate substance for development of a new type of anti-Staphylococcus aureus drug.

Provided are antibacterial phages that selectively kill bacteria having a drug resistance gene or the like. Antibacterial phage for this includes CRISPR-Cas13a with a target sequence that recognizes a specific gene as a target. This target sequence is designed as a spacer sequence for crRNA of 14-28 bases. Specific genes are drug resistance genes and toxins. The drug resistance genes are included in bacterial genomes and / or plasmids having one or any combination of the group including: methicillin-resistant Staphylococcus aureus, vancomycin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, penicillin-resistant pneumococcus, multidrug-resistant Pseudomonas aeruginosa, multidrug-resistant Pseudomonas aeruginosa, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant cephalosporins, third-generation cephalosporin-resistant Pseudomonas aeruginosa, third-generation cephalosporin-resistant E. coli, and fluoroquinolone-resistant E. coli.

The application discloses a chromogenic differential culture medium for separating duck Riemerella anatipestifer and application thereof, and belongs to the field of microorganism detection. The application provides the chromogenic differential culture medium based on physiological and biochemical characteristics of the duck Riemerella anatipestifer, and the chromogenic differential culture medium takes polymyxin B and vancomycin as specific antibiotics and takes X-Glu as a chromogenic substrate. The experimental results show that the chromogenic differential culture medium can efficiently inhibit growth of miscellaneous bacteria, and the duck Riemerella anatipestifer colony presents a characteristic color, so that the dual functions of selective culture and rapid identification are realized; the duck Riemerella anatipestifer identification method developed based on the chromogenic differential culture medium has the advantages of good selectivity, intuitive identification, simple operation, accurate results and the like, and the application provides new materials and methods for identification of the duck Riemerella anatipestifer and diagnosis of duck Riemerella anatipestifer disease.

The application discloses a series of eugenol-quaternary phosphonium salt conjugates and antibacterial application thereof. The series of compounds are obtained by introducing a quaternary phosphonium salt fragment on a phenolic hydroxyl group of eugenol as a leading compound, so that a series of eugenol-quaternary phosphonium salt conjugates are obtained, and the structural general formula is shown in the following formula (I). The series of compounds exhibit excellent antibacterial activity, and the inhibitory activity on common gram-positive bacteria such as staphylococcus aureus and enterococcus faecium and methicillin-resistant staphylococcus aureus is equivalent to that of vancomycin, a glycopeptide antibiotic. Through structural modification, the water solubility and antibacterial activity of eugenol are improved, and the hemolytic toxicity and cytotoxicity are relatively low. Therefore, the eugenol-quaternary phosphonium salt conjugate has the potential to be further developed as a new type of antibacterial drug.

This invention discloses a dual-recognition electrochemical sensor, its preparation method, and its application. The sensor comprises: (1) a working electrode modified with a molecularly imprinted polymer membrane; and (2) a vancomycin-modified copper-based metal-organic framework nanoenzyme signal probe. This signal probe specifically binds to the cell wall of Gram-positive bacteria and catalyzes the oxidation of o-phenylenediamine by peroxide to generate an electrochemical signal. During detection, the target bacteria are first captured by the molecularly imprinted layer, and the signal probe binds to the bacterial cell via vancomycin, forming a "sandwich" structure. The change in current signal is detected by differential pulse voltammetry to achieve quantitative analysis. The sensor of this invention has a detection limit as low as 1.1 CFU / mL and a linear range of 4 × 10⁻⁶. 1 -4×10 8 The CFU / mL concentration exhibits good selectivity and stability in complex samples such as cerebrospinal fluid. The preparation method of this invention is simple, low-cost, and highly sensitive, and can be used for ultrasensitive detection of Listeria monocytogenes in fields such as central nervous system infections and food safety monitoring.

Bacterial infections evading the current antibiotic arsenal warrant new treatment options. The mainstay treatment for Clostridium difficile infections involves administration of the broad-spectrum antibiotic vancomycin, which also depletes the gut microbiome and its natural defenses. This leads to recurrent C. difficile infections in 20-30% of patients. Alternative treatment options are limited, triggering a perpetual cycle of relapse and recovery that may eventually lead to death. Keratinicyclin B represents a glycopeptide antibiotic chemotype with a mechanism of action that is selective for Clostridia. When combined, vancomycin (or other glycopeptide antibiotic) and keratinicyclin B interact synergistically to inhibit the growth of C. difficile at concentrations far lower than their respective minimal inhibitory concentrations. Such a combination therapy could allow for targeted colonization clearance at low antibiotic doses, thereby minimizing toxicity and reducing the likelihood of relapse.

The invention discloses laggera pterodonta carbon dots as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method of the laggera pterodonta carbon dots comprises the following steps: dispersing laggera pterodonta fine powder in distilled water, and stirring and pyrolyzing on a heating table; and diluting the pyrolysis product with distilled water, centrifuging, taking supernate, filtering with a filter membrane, dialyzing, and freeze-drying to obtain the carbon dots. The average particle size of the obtained carbon dots is 4.51 + / -1.04 nm. The laggera pterodonta carbon dots prepared by the invention show strong inhibitory activity on various gram-positive bacteria (such as Listeria monocytogenes and methicillin-resistant staphylococcus aureus MRSA) and fungi (such as Candida albicans), and are particularly effective on clinically-difficult drug-resistant strains, such as vancomycin-resistant enterococcus (VRE) and MRSA; the compound can be applied to preparation of novel antibacterial drugs, antibacterial dressings, disinfectants or preservatives, and has the advantages of wide raw material sources, simple preparation method, low cost, environmental friendliness and the like.

This invention belongs to the field of drug detection technology, and relates to a platinum-iridium bimetallic nanozyme, its preparation method, and its application in immunochromatographic detection. The method includes: first, preparing a bimetallic nanozyme with a platinum core and an iridium shell; then, conjugating it with an antibody to create a colorimetric enhanced immunolabel. Based on this, a competitive immunochromatographic test strip is constructed, with the corresponding drug antigen immobilized on the T line and a quality control capture agent immobilized on the C line. During detection, the sample and label are mixed and added dropwise. If the sample does not contain the target drug, the labeled antibody binds to the antigen on the T line, resulting in color development; if the target drug is present, it competes with the T line for binding to the labeled antibody, leading to a weakening of the T line signal. A colorimetric solution is added, utilizing the catalytic activity of the nanozyme to amplify the signal, significantly improving sensitivity. This invention achieves detection limits of 0.41 ng / mL for vancomycin and 0.12 ng / mL for chlorpheniramine maleate, exhibiting advantages such as speed, high sensitivity, and ease of operation, making it suitable for therapeutic drug monitoring and trace drug residue detection.

The invention discloses a construction method and application of an Eriocheir sinensis intestinal flora deletion model, the method comprises the following steps: feeding Eriocheir sinensis with a feed mixed with mixed antibiotics for 96 hours to obtain the Eriocheir sinensis intestinal flora deletion model; the mixed antibiotic is prepared from metronidazole, neomycin and vancomycin. A plate culture method verifies that the optimized core antibiotic concentration group can enable the clearance rate of intestinal content florae to reach 95% or above and the clearance rate of fecal florae to reach 90% or above. According to the method, the intestinal flora deletion model of the eriocheir sinensis is constructed for the first time, the method has the advantages of being high in removal efficiency, good in repeatability, small in stress and the like, the flora is restorable after drug administration is stopped, and a standardized experimental tool is provided for studying the intestinal-brain axis mechanism, physiological metabolism and healthy breeding of crustacean.

The invention relates to a vancomycin-resistant enterococcus genome recovery method based on second-generation metagenome data, and the method comprises the following steps: carrying out quality control and splicing on second-generation metagenome sequencing data, and carrying out antibiotic resistance gene annotation and species annotation on a contig level; and carrying out secondary antibiotic resistance gene and species annotation on a metagenome assembly genome level through binning, so as to accurately identify vancomycin-resistant enterococcus and restore the genome.

The invention provides nitrate reducing bacteria C381 as well as a method and application thereof. The nitrate reducing bacteria C381 is preserved in China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36842; the invention provides a novel oral cavity probiotic nitrate reducing bacteria C381, the nitrate reducing bacteria C381 has an inhibition effect on periodontal disease bacteria, and the nitrate reducing bacteria C381 is sensitive to antibiotics such as erythromycin, piperacillin, minocycline, doxycycline, cefazolin, tetracycline, amikacin, gentamicin, vancomycin and cefoperazone, and can be used for preparing oral cavity probiotics for treating periodontal disease bacteria. And the product has good survival ability in the oral cavity.

The invention discloses a biological source manganese oxide material as well as a preparation system and application thereof. The biological source manganese oxide is obtained by oxidizing Mn (II) in vitro by Mn (II) oxidase PomA. The biogenic manganese oxide has a relatively strong degradation effect on five antibiotics such as streptomycin, vancomycin, ciprofloxacin, sulfamethoxazole and oxytetracycline.

A vancomycin derivative having a structure as shown in formula (I), a preparation method therefor, a pharmaceutical composition, and a use. A variety of sulfonium or sulfur-containing structural fragments having aromatic linkers are introduced at four positions of a vancomycin parent nucleus, which significantly enhances the antibacterial activity and shows the potential for the intrinsic resistance against Gram-negative bacteria while achieving high safety. Furthermore, the vancomycin derivative also shows antiviral activity.

The invention provides bacillus C367 as well as a method and application thereof. The bacillus C367 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36841; the bacillus C367 is separated from the Inner Mongolia cheese; the bacillus C367 can be used for preparing medicines for treating or preventing periodontal diseases; the invention provides a novel oral cavity probiotic bacillus C367, the bacillus C367 has an inhibition effect on periodontal disease bacteria, and the bacillus C367 is sensitive to antibiotics such as minocycline, amikacin, tetracycline, erythromycin, cefoperazone, streptomycin, kanamycin, gentamicin, vancomycin and ceftriaxone, and has good survival ability in an oral cavity.

The invention discloses lactobacillus gasseri with a lipid-lowering function and application of the lactobacillus gasseri, and belongs to the technical field of functional probiotic screening and application. The lactobacillus gasseri with the lipid-lowering function is classified and named as lactobacillus gasseri LGI 6-1, and is preserved in the China General Microbiological Culture Collection Center on July 15, 2024, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.31285. The lactobacillus gasseri with the lipid-lowering function has the advantages that the lactobacillus gasseri with the lipid-lowering function can be used for preparing the lipid-lowering food; the lactobacillus gasseri is separated from excrement of healthy infants, can reduce lipid accumulation and the content of cholesterol and triglyceride, effectively prevents and relieves hyperlipidemia and obesity, has relatively strong tolerance to artificial gastrointestinal fluid, is sensitive to antibiotics such as tetracycline and vancomycin, cannot dissolve blood cells, has no toxic effect on organisms, and can be used for preventing and treating hyperlipidemia and obesity. The compound has good biological safety, can be added into functional food, special medical food, health care products or medicines, and has a wide application prospect.